Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Monday, July 25th. For the reporting quarter, equity analysts expect the stock to deliver $2.88 in earnings per share (EPS). A total of 8.32M shares exchanged hands, whereas the company’s average trading volume stands at 9.71M shares.
Advertisement
As far as the Street estimates are concerned, the analyst believes that it is a tad too high because Gilead is now in a tight spot and under pressure on both fronts, namely pricing and market share.
In case of Revenue Estimates, 19 analysts have provided their consensus Average Revenue Estimates for Gilead Sciences, Inc.as 7.52 Billion.
The consensus EPS estimate that analysts have on Gilead Sciences, Inc.
Insider Activity: Corporate insiders look pessimistic about the outlook of the company stock that they seem to offload shares while they have -21.26 retreated so far this year. (NASDAQ:GILD) tinted loss of -1% (-0.79 points) to US$78.06.
Zacks Investment Research has upgraded Gilead Sciences, Inc.(NASDAQ:GILD) to Hold in a statement released 9/14/2016.
The analyst reaffirmed Outperform rating and cut price target to $95 from $115.
Young explains, “We are lowering our HCV revenues because we think street estimates are still too high considering continued price and market share pressure”, adding that for 2020, the analyst forecasts $9 billion in HCV sales compared to the Street’s estimate of $11 billion.
When we have a peek on stock’s historical trends we come to know that, the stock has slipped -0.77% in the past one week and plunged -2.55% during previous one month drive, the stock went down -6.53% during past quarter. The businesses 50 day moving average is 79.54 and its 200 day moving average is 86.33.
During last 5 trades the stock sticks nearly -0.77%. The share price of $77.62 is at a distance of 1.24 percent from its 52-week low and down -30.48 percent versus its peak. The stock’s market capitalization is 104.06B, it has a 52-week low of 76.67 and a 52-week high of 113.31.
The Relative Volume of the company is 0.8 and Average Volume (3 months) is 10.45 million. The firm has a market cap of $103.01 billion, a PE ratio of 6.85 and a beta of 1.06.
The company shows its Return on Assets (ROA) value of 32.7%. In the last six months the stock’s performance fell -13.54% while yearly performance of the company fell -29.07%.
Advertisement
While looking at the Stock’s Performance, Gilead Sciences, Inc. now shows a Weekly Performance of -0.77%, where Monthly Performance is -2.55%, Quarterly performance is -6.53%, 6 Months performance is -13.54% and yearly performance percentage is -29.07%. The company’s year to date (YTD) performance is at -22.49%. Average true range (ATR-14) of the company sets at 1.18, along with its weekly and monthly volatility of 1.53%, 1.50% respectively.
